Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma; Multicenter study

Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma; Multicenter study - Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma;Multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012561

Enrollment

200

Registered

2013-12-12

Start date

2013-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant soft tissue tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients inclusion 1.Clinical history of treatment for primary soft tissue sarcoma 2.The aim to use pazopanib is for local recurrent or metastatic tumor 3.The existence of tumors which can be evaluated by radiological examination when treatment using pazopanib is started.

Exclusion criteria

Exclusion criteria: Patients who are not treated in the registered institutions of Japanese Musculoskeletal Oncology Group will be excluded from this study.

Design outcomes

Primary

Measure	Time frame
Survival Progressive-free survival Side effect	—

Countries

Japan

Contacts

Public ContactDr. Tomoki Nakamura

Mie University Graduate School of Medicine Dept. of Orthopaedic Surgery

tomoki66@clin.medic.mie-u.ac.jp059-232-1111

Outcome results